Poster presented at the International Headache Congress (IHC) 2019 in Dublin, Ireland. Authors: Kelsey H. Satterly, Stephen B. Shrewsbury, John Hoekman Objective: To compare plasma exposure in the first two hours following administration of INP104 (dihydroergotamine mesylate [DHE] by Precision Olfactory Delivery [POD®]), Migranal® Nasal Spray, D.H.E. 45® (IV) or MAP0004 (oral inhalation)...

Poster presented at the International Headache Congress (IHC) 2019 in Dublin, Ireland. Authors: Sutapa Ray, Stephen Shrewsbury Objective: Ergot use in obstetrics dates back to 1100 BC in China, 370 BC by Hippocrates and 1808 in the US. However, it was not until 1918 that ergotamine was isolated, subsequently modified to DHE and...

Poster presented at International Headache Congress (IHC) 2019 in Dublin, Ireland Authors: Stephen B. Shrewsbury, Maria Jeleva, Jasna Hocevar-Trnka, Meghan Swardstrom Objective: 1) Establish safety and tolerability of repeated INP104 exposure 2) Explore efficacy of INP104 in migraineurs (compared to baseline) 3) Explore INP104 effects on Quality of Life and Healthcare Utilisation...

Impel is a proud sponsor of the 2nd annual Mississippi Headache Symposium, bringing together providers and patients for a great educational event. You can meet us at our booth for more information on our migraine program. ...

The Safety & Tolerability of INP104 is Currently Being Evaluated in the Company’s Recently Fully-Enrolled Pivotal Phase 3 “STOP-301” Trial New Data from a Patient Experience Survey Describe Dissatisfaction Levels with Current Available Treatments & Desire for New Options That Offer More Rapid & Complete Relief of Migraine Symptoms with a Lower Side Effect Profile SEATTLE, September...

Impel NeuroPharma will be attending the International Headache Congress (IHC) 2019 annual meeting. The team will present data from the INP104 clinical program. ...